Trading Information Summary - On July 25, 2025, Sely Medical (603716) closed at 31.22 yuan, up 2.7%, with a turnover rate of 34.88% and a trading volume of 666,300 shares, amounting to a total transaction value of 2.147 billion yuan [1] - The net inflow of main funds was 70.7018 million yuan, accounting for 3.29% of the total transaction value, while retail investors had a net inflow of 665,500 yuan, representing 0.03% of the total [1][3] Company Announcement Summary - Sely Medical announced that its stock price had deviated by more than 20% over three consecutive trading days, indicating abnormal trading activity. The company confirmed that there were no undisclosed significant information from its controlling shareholder and actual controller [1] - The company expects a net profit attributable to shareholders for the first half of 2025 to be between -55 million and -66 million yuan [1] - The controlling shareholder has a high cumulative pledge ratio, which investors should be aware of [1] - The joint venture, Huajiyuan Biotech's therapeutic vaccine project HJY-ATRQβ-001, received acceptance for clinical trial application from the National Medical Products Administration on June 6, 2025, but the success of subsequent clinical trials remains uncertain [1]

Summary of Key Points Core Viewpoint - The stock of Seli Medical (603716) experienced a 2.70% increase today, with a trading volume of 2.147 billion yuan and a turnover rate of 34.88%, despite a net sell-off of 18.83 million yuan by brokerage seats [2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange's "Dragon and Tiger List" due to a daily turnover rate of 32.26%, with a total net sell-off of 18.83 million yuan by brokerage seats [2]. - The top five brokerage seats accounted for a total transaction volume of 559 million yuan, with a buying amount of 270 million yuan and a selling amount of 289 million yuan, resulting in a net sell-off of 18.83 million yuan [2]. - The largest buying and selling brokerage was Guotai Junan Securities Headquarters, with buying and selling amounts of 126 million yuan and 138 million yuan, respectively [2]. Historical Performance - Over the past six months, the stock has appeared on the "Dragon and Tiger List" 34 times, with an average price increase of 1.69% the day after being listed and an average increase of 6.88% over the following five days [2]. Fund Flow - Today, the stock saw a net inflow of 103 million yuan in main funds, with a significant inflow of 129 million yuan from large orders, while large orders experienced a net outflow of 26.45 million yuan [2]. - In the past five days, the net inflow of main funds totaled 296 million yuan [2]. Financial Performance - The company reported a first-quarter revenue of 287 million yuan, representing a year-on-year decline of 40.75%, and a net loss of 14.32 million yuan [2]. - On July 15, the company issued a half-year performance forecast, estimating a net loss between 66 million yuan and 55 million yuan [3].

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-067 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 塞力斯医疗科技集团股份有限公司（以下简称"公司"）股票连续3个交 易日内日收盘价格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》 的有关规定，属于股票交易异常波动情形。 经公司自查，并向控股股东赛海（上海）健康科技有限公司（以下简称 "赛海科技"）及实际控制人温伟先生发函核实，截至本公告披露日，控股股东 及实际控制人不存在应披露而未披露的重大信息，包括但不限于重大资产重组、 股份发行、重大交易类事项、业务重组、股份回购、破产重整、重大业务合作、 引进战略投资者等重大事项。 风险提示详见本公告"三、相关风险提示"，公司倡导价值投资并专注 于主业的发展，敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 （一）生产 ...

Group 1 - The core viewpoint of the articles highlights the increasing activity in the innovative drug sector, driven by favorable government policies and the introduction of a commercial health insurance directory for innovative drugs [1][2] - Since 2025, the government has proposed multiple policies to optimize drug procurement and support innovative drugs, indicating a positive policy environment for the pharmaceutical industry [1] - The 11th batch of national drug procurement is underway, with expectations for optimized rules and price reductions, moving away from a focus on minimum pricing to a more quality-controlled approach [1] Group 2 - Ever since the 14th Five-Year Plan, a total of 402 new drugs have been included in the medical insurance directory, with innovative drug spending projected to reach 3.9 times that of 2020 by 2024, reflecting a 40% annual growth rate [2] - The establishment of a commercial health insurance directory for innovative drugs will provide a supplementary payment channel for drugs not included in the national medical insurance directory, with over 100 drugs already submitted for approval [2] - The precise adjustment of medical insurance policies is reshaping the pharmaceutical industry ecosystem, transitioning from price wars to value wars, and clearing out low-quality production capacity to create market space for high-quality enterprises [2]

Core Viewpoint - The company, Saily Medical, has experienced a significant stock price increase of over 250% this year, despite reporting a tenfold increase in losses for the first half of 2025, highlighting a stark contrast between stock performance and financial results [2][9]. Financial Performance - The company expects a net loss attributable to shareholders of between 55 million to 66 million yuan for the first half of 2025, which is an increase in losses of 50.23 million to 61.23 million yuan compared to the same period last year [3]. - The first quarter of 2025 showed a net loss of 14.32 million yuan, indicating a worsening trend in the second quarter [3][6]. - Revenue for the first half of 2025 is projected to decline by 40.75% compared to the previous year, with a significant drop in net profit of 553.66% [4][6]. Business Operations - The company has been trapped in a cycle of increasing revenue without corresponding profit since 2020, with a net profit loss that has expanded for four consecutive years [4][6]. - The main business areas, particularly the SPD business, are showing signs of fatigue, with revenue growth of only 10.23% in 2024, while costs have risen nearly in tandem, leading to minimal improvement in gross margins [6][10]. Market Position and Investor Sentiment - Despite the financial struggles, Saily Medical's stock price has surged, creating a disconnect between market valuation and financial fundamentals, raising concerns about sustainability [10][14]. - Analysts suggest that the current high valuation may not be supported by the company's fundamentals, and caution against blindly following market trends without a thorough analysis of the company's core business improvements [10][14]. Strategic Direction and Challenges - The company is focusing on a transformation towards medical intelligence, including areas like brain-computer interfaces and innovative drugs, but faces skepticism regarding the feasibility and timeline of these initiatives [10][12]. - R&D investment remains low, with only 2.58% of revenue allocated to R&D in 2024, which is insufficient to support the ambitious multi-line strategy [10][12]. Financial Health and Credit Rating - Saily Medical has faced liquidity pressures, with multiple instances of overdue repayment of raised funds, leading to criticism of management [12][13]. - The company's credit rating was downgraded from "BBB-" to "BB+" due to increasing losses, long customer payment cycles, and high financial leverage, indicating a deteriorating financial outlook [14].

Market Overview - As of July 23, the Shanghai Composite Index closed at 3582.30 points, with a slight increase of 0.44 points, representing a change of 0.01% [1] - The Shenzhen Component Index closed at 11059.04 points, down by 40.79 points, a decrease of 0.37% [1] - The ChiNext Index closed at 2310.67 points, with a minor decline of 0.19 points, or 0.01% [1] Trading Activity - A total of 101 A-shares had a turnover rate exceeding 20% on this day, indicating significant trading activity [1] - Notably, C Shanda and C Jiyuan had turnover rates above 50%, with 82.89% and 80.75% respectively, indicating a high level of liquidity and interest in these stocks [1] Top Stocks by Turnover Rate - C Shanda (301609) closed at 66.85 CNY, with a turnover rate of 82.89% and a remarkable increase of 356.00% [1] - C Jiyuan (603262) closed at 40.75 CNY, with a turnover rate of 80.75% and a significant rise of 274.54% [1] - Other notable stocks with high turnover rates include: - Guanlong Energy (301151) at 24.11 CNY, turnover rate of 72.29%, down by 5.67% [1] - Weiman Sealing (301161) at 29.81 CNY, turnover rate of 66.12%, down by 16.05% [1] - Southern Road Machinery (603280) at 34.75 CNY, turnover rate of 64.76%, up by 10.00% [1] Additional Noteworthy Stocks - Other stocks with notable trading activity include: - Sichuan Jinding (600678) at 11.15 CNY, turnover rate of 51.91%, down by 4.21% [1] - Baijia Technology (835857) at 9.56 CNY, turnover rate of 47.74%, up by 17.16% [1] - Jindun Co. (300411) at 15.77 CNY, turnover rate of 43.27%, down by 1.93% [1]

Group 1 - The DRG/DIP concept increased by 0.27%, ranking 10th among concept sectors, with 8 stocks rising, including Saily Medical which hit the daily limit, and Jiayuan Technology, Jiahe Meikang, and Huayu Software showing gains of 4.63%, 3.85%, and 1.75% respectively [1][2] - The leading decliners in the sector included Kechuang Information, Rongke Technology, and Maidi Technology, which fell by 6.02%, 2.53%, and 2.00% respectively [1][2] Group 2 - The DRG/DIP concept sector saw a net inflow of 362 million yuan, with 14 stocks receiving net inflows, and 7 stocks exceeding 10 million yuan in net inflow [2][3] - Saily Medical led the net inflow with 336 million yuan, followed by Donghua Software, Jiayuan Technology, and Jiuyuan Yinhai with net inflows of 40.39 million yuan, 16.30 million yuan, and 16.22 million yuan respectively [2][3] Group 3 - In terms of net inflow ratios, Saily Medical, Jiayuan Technology, and Jiuyuan Yinhai had the highest ratios at 21.82%, 6.22%, and 5.62% respectively [3][4] - The trading volume and turnover rates for Saily Medical were notably high, with a turnover rate of 28.92% and a daily increase of 10.01% [3][4]

Group 1 - The cell immunotherapy concept index rose by 0.56%, ranking fourth among concept sectors, with 25 stocks increasing in value [1] - Notable gainers included Nanjing Xinbai, Saily Medical, and *ST Biology, which reached their daily limit up, with increases of 8.61%, 7.86%, and 7.18% respectively [1] - The largest declines were seen in Chengda Pharmaceutical, Hainan Haiyao, and Jiuzhitang, with decreases of 13.12%, 6.31%, and 5.07% respectively [1] Group 2 - The cell immunotherapy sector experienced a net outflow of 213 million yuan in main funds, with 27 stocks seeing net inflows [2] - Saily Medical led the net inflow with 336 million yuan, followed by Zhaoyan New Drug, Nanjing Xinbai, and Northeast Pharmaceutical with net inflows of 203 million yuan, 111 million yuan, and 77.41 million yuan respectively [2] - The net inflow ratios for Nanjing Xinbai, Saily Medical, and Zhaoyan New Drug were 43.57%, 21.82%, and 12.72% respectively [3] Group 3 - The cell immunotherapy sector's performance was highlighted by the significant trading volumes and turnover rates of leading stocks, indicating strong investor interest [3][4] - Stocks like Saily Medical and Nanjing Xinbai showed high turnover rates of 28.92% and 2.96% respectively, reflecting active trading [3] - The overall market sentiment in the cell immunotherapy sector remains positive despite some individual stock declines [2][6]

Group 1 - The stock of Sely Medical (603716) increased by 1.65% with a turnover rate of 31.95% and a trading volume of 1.591 billion yuan, showing a fluctuation of 9.44% [1] - Institutional investors net bought 82.4985 million yuan, while brokerage seats collectively net sold 34.0815 million yuan [1][2] - The stock was listed on the trading board due to a daily turnover rate of 29.57%, with the top five trading departments having a total transaction of 372 million yuan, resulting in a net purchase of 48.417 million yuan [2][3] Group 2 - Over the past six months, the stock has appeared on the trading board 31 times, with an average price increase of 1.21% the day after being listed and an average increase of 3.99% in the following five days [4] - The stock saw a net inflow of 18.3451 million yuan today, with a significant single order net inflow of 25.2854 million yuan, while large orders experienced a net outflow of 6.9403 million yuan [4] - The company's Q1 report indicated a revenue of 287 million yuan, a year-on-year decrease of 40.75%, and a net loss of 14.3209 million yuan [4] Group 3 - On July 15, the company forecasted a net loss for the first half of the year between 55 million yuan and 66 million yuan [5] - The trading data on July 22 showed significant buying from various brokerage firms, with the top buyer being Guotai Junan Securities Headquarters, purchasing 92.1655 million yuan [5]

Core Viewpoint - The company, Seer Medical Technology Group Co., Ltd., has decided not to exercise the early redemption rights for its convertible bonds, despite meeting the conditions for redemption due to stock price performance [1][6]. Group 1: Convertible Bond Redemption - The company's stock price has met the condition of being above 130% of the conversion price for at least 15 trading days within a 30-day period, triggering the redemption clause for the "Seer Convertible Bonds" [1][6]. - The board of directors has resolved not to redeem the "Seer Convertible Bonds" early, considering current market conditions and the protection of investor interests [1][7]. - The company will not exercise the early redemption rights for the next three months, and if the redemption conditions are met again after October 21, 2025, the board will reconvene to decide on the matter [1][6]. Group 2: Convertible Bond Issuance and Terms - The company issued 5.4331 million convertible bonds at a face value of 100 yuan each, totaling 534.698 million yuan, with the net proceeds after expenses amounting to 532.698 million yuan [1][2]. - The initial conversion price was set at 16.98 yuan per share, with the conversion period running from March 1, 2021, to August 20, 2026 [2][3]. - The conversion price has been adjusted multiple times, with the latest adjustment reducing it from 12.50 yuan to 12.00 yuan per share, effective from February 6, 2025 [5][6]. Group 3: Compliance and Oversight - The company has adhered to necessary decision-making procedures regarding the non-redemption of the convertible bonds, in compliance with relevant regulations and guidelines [7][8]. - The sponsor institution has confirmed that the decision not to redeem the bonds early is in line with legal requirements and the company's offering documents [7][8].